Consistent with our earlier observations about the NRF2/KLF5/SLC1A5 pathway in cultured cells, immunoblotting of the MT-101 tumor tissues showed that the accumulation of NRF2, KLF5, and SLC1A5 was obviously reduced upon CsA treatment and upon the CsA and CB-839 combination treatment (Supplementary Fig. 11I). The gene discussed is NFE2L2; the disease is neoplasm.